FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 90 filers reported holding FATE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $685,000 | -3.0% | 11,708 | -1.7% | 0.02% | -9.1% |
| Q3 2021 | $706,000 | -31.7% | 11,915 | 0.0% | 0.02% | -26.7% |
| Q2 2021 | $1,034,000 | +123.3% | 11,915 | +112.4% | 0.03% | +114.3% |
| Q1 2021 | $463,000 | -13.8% | 5,610 | -5.1% | 0.01% | -17.6% |
| Q4 2020 | $537,000 | -38.8% | 5,910 | -92.4% | 0.02% | -34.6% |
| Q2 2018 | $877,000 | +12.0% | 77,304 | -3.7% | 0.03% | -3.7% |
| Q1 2018 | $783,000 | – | 80,247 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |